Activation mechanisms of STAT5 by oncogenic Flt3-ITD

C Choudhary, C Brandts, J Schwable… - Blood, The Journal …, 2007 - ashpublications.org
C Choudhary, C Brandts, J Schwable, L Tickenbrock, B Sargin, A Ueker, FD Böhmer…
Blood, The Journal of the American Society of Hematology, 2007ashpublications.org
Mutations in the receptor tyrosine kinase Flt3 represent a very common genetic lesion in
acute myeloid leukemia (AML). Internal tandem duplication (ITD) mutations clustered in the
juxtamembrane domain are the most frequent and best characterized mutations found in
Flt3. Oncogenic activation of Flt3 by ITD mutations is known to activate aberrant signaling
including activation of STAT5 and repression of myeloid transcription factors Pu. 1 and
c/EBP-alpha. However, the mechanisms of STAT5 activation by Flt3-ITD remain unclear …
Mutations in the receptor tyrosine kinase Flt3 represent a very common genetic lesion in acute myeloid leukemia (AML). Internal tandem duplication (ITD) mutations clustered in the juxtamembrane domain are the most frequent and best characterized mutations found in Flt3. Oncogenic activation of Flt3 by ITD mutations is known to activate aberrant signaling including activation of STAT5 and repression of myeloid transcription factors Pu.1 and c/EBP-alpha. However, the mechanisms of STAT5 activation by Flt3-ITD remain unclear. Using small molecule inhibitors and cell lines deficient for Src family kinases or Jak2 or Tyk2, here we show that Flt3-ITD–induced STAT5 activation is independent of Src or Jak kinases. Also, overexpression of SOCS1, an inhibitor of Jak kinases, inhibited IL-3– but not Flt3-ITD–mediated STAT5 activation. Furthermore, in vitro kinase assays revealed that STAT5 is a direct target of Flt3. Taken together, our data provide the mechanistic basis of STAT5 activation by Flt3-ITD.
ashpublications.org